false 0000876378 0000876378 2023-02-21 2023-02-21
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
_________________
 
FORM 8-K
_________________
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
February 21, 2023
Date of Report (date of earliest event reported)
_________________
 
Asensus Surgical, Inc.
(Exact name of Registrant as specified in its charter)
_________________
 
Delaware
(State or other jurisdiction of
incorporation or organization)
0-19437
(Commission
File Number)
11-2962080
(I.R.S. Employer
Identification Number)
 
1 TW Alexander Drive, Suite 160
Durham, NC 27703
(Address of principal executive offices)
919-765-8400
(Registrant’s telephone number, including area code)
 
Not Applicable
(Former name or former address, if changed since last report)
_________________
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
  
Trading symbol
  
Name of each exchange on which registered
Common Stock
$0.001 par value per share
  
ASXC
  
NYSE American
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 
 
 
Item 7.01 Regulation FD Disclosure
 
On February 21, 2023, Asensus Surgical, Inc. (the “Company”) is hosting an Investor Day to provide a corporate update to investors. The Company notified investors of the date of the Investor Day via press release issued on January 30, 2023. The information provided during such Investor Date is furnished as Exhibit 99.1 to this Form 8‑K.
 
The information in this Item 7.01 and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
 
 
Item 8.01 Other Events.
 
The Company issued a press release just prior to hosting its Investor Day on February 21, 2023. The press release is attached as Exhibit 99.2 to this Form 8-K.
 
Item 9.01         Financial Statements and Exhibits.
 
(d)
Exhibit
 
 
Exhibit No.
Description
 
 
99.1
 
 
99.2
 
 
104
Cover Page Interactive Data File (formatted in inline XBRL)
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
  ASENSUS SURGICAL, INC.
   
Date: February 21, 2023  /s/ Shameze Rampertab
 
Shameze Rampertab         
Executive Vice President and Chief Financial Officer
 
 
TransEnterix (AMEX:TRXC)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more TransEnterix Charts.
TransEnterix (AMEX:TRXC)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more TransEnterix Charts.